Legal & General Group
SKYE icon

Legal & General Group’s Skye Bioscience SKYE Stock Holding History

Legal & General Group’s Portfolio SKYE Stock Details SKYE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-186
Closed -$2.36K – 3572
2025
Q1 		$2.36K Hold
186
– – ﹤0.01% 3345
2024
Q4 		$4.21K Hold
186
– – ﹤0.01% 3352
2024
Q3 		$5.81K Hold
186
– – ﹤0.01% 3356
2024
Q2 		$11.9K Buy
+186
New +$17.7K ﹤0.01% 3250

Other funds holding SKYE

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Schonfeld Strategic Advisors
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
Driehaus Capital Management
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Legal & General Group's SKYE Position: Q2 2025 in Review

Legal & General Group sold out of Skye Bioscience (SKYE) in Q2 2025, closing a stake of 186 shares — an estimated $2.36K sold.

Legal & General Group first reported a position in SKYE in Q2 2024 and held it in 4 quarters. The position peaked at $11.9K in Q2 2024. 55 funds tracked by Wall St. Rank hold SKYE as of Q2 2025.

  • Legal & General Group reported no remaining Skye Bioscience position as of Q2 2025 after selling out during the quarter.
  • Legal & General Group sold 186 Skye Bioscience shares in Q2 2025, an estimated $2.36K.
  • Legal & General Group first reported a position in Skye Bioscience in Q2 2024 and held it in 4 quarters.
  • Legal & General Group's Skye Bioscience position peaked at $11.9K in Q2 2024.
  • 55 funds tracked by Wall St. Rank held Skye Bioscience as of Q2 2025.

Based on Legal & General Group's 13F filing for Q2 2025, filed 12 Aug 2025.